Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, has appointed Maxine Gowen to its board of directors.
“Gowen brings a wealth of industry knowledge and experience along with organization leadership, which further enhances our Board’s ability to help guide Idera into the future as we continue our transition towards becoming a company focused on delivering approved therapies for patients suffering from certain cancers and rare diseases,” commented Idera’s CEO Vincent Milano.
Gowen is the founding President and CEO of Trevena. She also serves on the board of directors of Akebia Therapeutics and the state and national biotechnology industry associations, PA BIO and BIO. Prior to Trevena, she held a variety of leadership roles at GSK over a period of fifteen years.
“The addition of Gowen significantly strengthens our board’s ability to guide Idera’s strategic clinical development endeavors through her vast industry drug development and leadership experience,” noted Jim Geraghty, Chairman of Idera’s board of directors.
Based in Cambridge, Mass, Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera is developing a third generation antisense technology platform that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.
Idera’s board consists of Geraghty, Milano, Sudhir Agrawal, Julian C. Baker, Youssef El Zein, Mark Goldberg, Kelvin M. Neu, William S. Reardon, Eve Slater and Gowen.